drugset / Trial / NCT07501169
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Phase 2
Not yet recruiting
33 enrolled
Sichuan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collabSichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an single-arm, multicenter phase II study to evaluate the safety and efficacy of Sacituzumab Tirumotecan (sac-TMT) plus anlotinib in previously treated extensive-stage small cell lung cancer (ES-SCLC). The study is expected to enroll up to 33 eligible patients.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2027-08-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 4 mg/kg | Intravenous |